Abstract
Conflicts of interest: none declared. Madam, The previous World Health Organization’s (WHO) classification of malignant lymphomas defined CD4+/CD56+ blastic natural killer (NK)‐cell lymphoma arising from NK‐cell precursors. However, recent studies suggest a plasmacytoid dendritic cell precursor.1, 2 Therefore, the new WHO classification has been recently changed to ‘CD4+/CD56+ haematodermic neoplasm’. CD4+/CD56+ haematodermic neoplasm is a clinically aggressive neoplasm with a median survival of 14 months.3 Human T‐cell leukaemia virus type 1 (HTLV‐1) has been classically associated with adult T‐cell leukaemia/lymphoma (ATLL). A recent review of PubMed for key terms ‘NK‐lymphoma’, ‘HTLV‐1’ and ‘CD4+ CD56+ lymphoma’ did not reveal any cases of CD4+/CD56+ blastic NK‐cell lymphoma in association with HTLV‐1 infection. The incidence of HTLV‐1 infection is increased in endemic areas such as central Africa, the Caribbean islands, Fukuoka, Japan and South America.4, 5 It has been well documented that infectious agents such as Epstein–Barr virus (EBV) and HTLV‐1 are associated with lymphomas. Classically, EBV infection is associated with nasal‐type NK lymphomas.6 Currently there is no infectious aetiology associated with CD4+/CD56+ haematodermic neoplasm.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
